Across the recent three months, 14 analysts have shared their insights on Regeneron Pharmaceuticals (NASDAQ:REGN), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 5 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 3 | 4 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $838.07, a high estimate of $975.00, and a low estimate of $745.00. This upward trend is evident, with the current average reflecting a 9.77% increase from the previous average price target of $763.46.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Eliana Merle | Barclays | Announces | Overweight | $923.00 | - |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $765.00 | $745.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $975.00 | $865.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $950.00 | $850.00 |
| Matthew Biegler | Oppenheimer | Raises | Outperform | $865.00 | $750.00 |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $769.00 | $768.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $800.00 | $745.00 |
| Carter Gould | Cantor Fitzgerald | Raises | Overweight | $800.00 | $740.00 |
| Gregory Renza | Truist Securities | Lowers | Buy | $818.00 | $820.00 |
| Cory Kasimov | Evercore ISI Group | Raises | Outperform | $875.00 | $750.00 |
| Gregory Renza | Truist Securities | Raises | Buy | $820.00 | $798.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $860.00 | $627.00 |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $768.00 | $767.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $745.00 | $700.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regeneron Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regeneron Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
Get to Know Regeneron Pharmaceuticals Better
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Breaking Down Regeneron Pharmaceuticals's Financial Performance
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, Regeneron Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 2.51% as of 31 December, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.74%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.72% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.09% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Regeneron Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to comment